Can immune cells revive lung cancer treatment?
NCT ID NCT07498595
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether combining a patient's own immune cells (called TILs) with a targeted therapy drug can safely treat advanced lung cancer that has stopped responding to standard targeted treatment. Researchers will enroll 50 adults with EGFR-mutant non-small cell lung cancer. The main goal is to check for side effects, not yet to prove the treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tumor-infiltrating lymphocytes (TILs) combined with a third-generation EGFR-TKI
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced lung cancer whose tumors have stopped responding to targeted therapy.
- What could go wrong
- This is a very early, small safety study (50 people) and may not show clear benefit. The treatment involves surgery to collect immune cells and carries risks like infection or immune reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR-TKI-RESISTANT NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.